RegenxBio attracts more companies. Why Loxo is important to observe today

We hope you all took advantage of the Thanksgiving holiday to rest and relax. We did.

In Today’s NEWS

RegenxBio Offers Rocket Pharmaceuticals exclusive, worldwide, rights to adenoviral vector NAV AAV9 for the development of treatments for Danon Disease

RegenxBio (RGNX) announced that it awarded an exclusive, worldwide, license agreement to Rocket Pharmaceuticals (RCKT) so it can develop gene therapy for Danon disease. The exclusive license enables Rocket to use RegenxBio's . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.